Related Experiment Videos
[Oligoasthenoteratozoospermia in valproic acid therapy]
1Med. Zentrum für Hautkrankheiten am Klinikum der Philipps-Universität Marburg, Abt. Dermatologie SP Andrologie.
Zeitschrift Fur Hautkrankheiten
|February 15, 1988
Summary
Valproic acid therapy for epilepsy can cause low sperm count, poor motility, and abnormal sperm morphology (oligoasthenoteratozoospermia). Reducing the dose restored sperm parameters and led to a successful pregnancy.
Area of Science:
- Reproductive Medicine
- Neurology
- Pharmacology
Background:
- Valproic acid is a widely used antiepileptic drug.
- Oligoasthenoteratozoospermia is a common cause of male infertility.
- The potential impact of valproic acid on male fertility requires further investigation.
Observation:
- Two male patients with epilepsy were treated with high-dose valproic acid (over 1000 mg daily).
- Both patients presented with oligoasthenoteratozoospermia.
- Sperm parameters were assessed before and after dose modification.
Findings:
- High-dose valproic acid therapy was associated with oligoasthenoteratozoospermia in both cases.
- Reducing the daily valproic acid dose to 150 mg resulted in normalization of sperm parameters.
- One patient achieved pregnancy after the dose reduction and 5 years of infertility.
Implications:
- Valproic acid dosage may significantly impact male reproductive health.
- Fertility assessment and counseling should be considered for men on long-term valproic acid therapy.
- Lowering valproic acid dosage may be a viable strategy to improve sperm quality and fertility outcomes.